+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biosimilars: Global Strategic Business Report

  • PDF Icon

    Report

  • 193 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227769

Global Biosimilars Market to Reach $121.7 Billion by 2030

The global market for Biosimilars estimated at US$29.2 Billion in the year 2022, is projected to reach a revised size of US$121.7 Billion by 2030, growing at a CAGR of 19.6% over the analysis period 2022-2030. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is projected to record 20% CAGR and reach US$56.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Recombinant Glycosylated Proteins segment is readjusted to a revised 20.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $8.7 Billion, While China is Forecast to Grow at 19% CAGR

The Biosimilars market in the U.S. is estimated at US$8.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$21.1 Billion by the year 2030 trailing a CAGR of 19% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.7% and 15.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12% CAGR.

Select Competitors (Total 46 Featured) -

  • Allergan Plc
  • Amgen Inc.
  • Biocon Ltd.
  • Biopartners GmbH
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc.
  • Dr. Reddy`s Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi
  • Intas Pharmaceuticals Ltd.
  • Mylan NV
  • Pfizer Inc.
  • Samsung Bioepis Co. Ltd.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Biosimilars

What is the estimated value of the Global Market for Biosimilars?

The Global Market for Biosimilars was estimated to be valued at $18.7 Billion in 2020.

What is the growth rate of the Global Market for Biosimilars?

The growth rate of the Global Market for Biosimilars is 20.3%, with an estimated value of $68.2 Billion by 2027.

What is the forecasted size of the Global Market for Biosimilars?

The Global Market for Biosimilars is estimated to be worth $68.2 Billion by 2027.

Who are the key companies in the Global Market for Biosimilars?

Key companies in the Global Market for Biosimilars include Allergan Plc, Amgen Inc., Biocon Ltd., Biopartners GmbH, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy`s Laboratories Ltd., Eli Lilly and Company, Fresenius Kabi and Intas Pharmaceuticals Ltd..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Biosimilars: An Introductory Prelude
  • Recent Market Activity
  • World Healthcare Sector Gears Up for Biosimilar Wave
  • Biosimilars Offer Great Promise Despite Challenges
  • The US & Europe Drive Momentum in Worldwide Biosimilars Sales
  • Emerging Markets also Offer Robust Growth Opportunities
  • R&D Funding: Crucial for Future Expansion of Biosimilars Market
  • Prevailing Economic Scenario Favors Funding Pattern
  • Biosimilars - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
  • Allergan Plc (Ireland)
  • Amgen, Inc. (USA)
  • Biocon Ltd. (India)
  • Biopartners GmbH (Switzerland)
  • Boehringer Ingelheim International GmbH (Germany)
  • Celltrion, Inc. (South Korea)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Eli Lilly and Company (USA)
  • Fresenius Kabi (Germany)
  • Intas Pharmaceuticals Ltd. (India)
  • Mylan N.V. (USA)
  • Pfizer, Inc. (USA)
  • Samsung Bioepis Co., Ltd. (Korea)
  • Sandoz International GmbH (Germany)
  • STADA Arzneimittel AG (Germany)
  • Teva Pharmaceutical Industries Ltd. (Israel)
3. MARKET TRENDS & DRIVERS
  • Slew of Product Approvals Scale Up Market Revenues
  • Biosimilar Approvals in Europe (as of H1 2018)
  • Biosimilar Approvals in the US (as of H1 2018)
  • Pipeline Biosimilar Products in the US (as of H1 2018)
  • Biosimilar Approvals in South Korea (as of H1 2018)
  • Patent Expiry of Major Biopharmaceutical Drugs Leads Way for Biosimilars
  • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
  • Cost Containment Measures Put Focus on Biosimilars
  • High Cost of Biologics - Favorable for Biosimilars
  • Efforts to Push Up Biosimilar Adoption Aid Market Expansion
  • Increasing Share of Biotech Drugs to Drive Biosimilars Market
  • Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues
  • Specific Guidelines for Biosimilars in Various Countries with Year of Publication
  • Biosimilars Regulatory Agencies in Select Regional Markets
  • Improvement in Nomenclature & Interchangeability Enhance Appeal & Image of Biosimilars
  • Human Insulin Biosimilars Eye Potential Opportunities
  • Monoclonal Antibodies - A Key Segment for Biosimilars
  • Approved Monoclonal Antibodies (2014-2017)
  • Rituximab Biosimilars to Proliferate the Market
  • Growing Incidence of Chronic Diseases & Ageing Population Widen Prospects for Biosimilars
  • Growing Biosimilars Market - A Clear Advantage for Bioseparation Technologies
  • Growth Restraints
  • Lack of Uniform Regulations
  • High Lead-time
  • High Manufacturing Costs
  • Difficulties in Delivery & Commercialization
  • Automatic Substitution
  • Biobetters: A Potential Industry Challenge
  • Other Impediments to Market Acceptance
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World 8-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
  • Table 3: World Recent Past, Current & Future Analysis for Recombinant Non-glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 4: World 8-Year Perspective for Recombinant Non-glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Recombinant Glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 6: World 8-Year Perspective for Recombinant Glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Recombinant Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World 8-Year Perspective for Recombinant Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 9: World Recent Past, Current & Future Analysis for Blood Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 10: World 8-Year Perspective for Blood Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 12: World 8-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Chronic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World 8-Year Perspective for Chronic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 15: World Recent Past, Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 16: World 8-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 18: World 8-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 19: World Biosimilars Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: USA 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 22: USA Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 23: USA 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
CANADA
  • Table 24: Canada Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 25: Canada 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 26: Canada Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: Canada 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
JAPAN
  • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 28: Japan Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 29: Japan 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 30: Japan Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 31: Japan 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
CHINA
  • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 32: China Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: China 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 34: China Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 35: China 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
EUROPE
  • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 36: Europe Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 37: Europe 8-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
  • Table 38: Europe Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Europe 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 40: Europe Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 41: Europe 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
FRANCE
  • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 42: France Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 43: France 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 44: France Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: France 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
GERMANY
  • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 46: Germany Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 47: Germany 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 48: Germany Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 49: Germany 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
ITALY
  • Table 50: Italy Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Italy 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 52: Italy Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 53: Italy 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
UNITED KINGDOM
  • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 54: UK Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 55: UK 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 56: UK Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: UK 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
REST OF EUROPE
  • Table 58: Rest of Europe Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 59: Rest of Europe 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 60: Rest of Europe Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 61: Rest of Europe 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
ASIA-PACIFIC
  • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: Asia-Pacific 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 64: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 65: Asia-Pacific 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
REST OF WORLD
  • Table 66: Rest of World Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 67: Rest of World 8-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2023 & 2030
  • Table 68: Rest of World Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: Rest of World 8-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Allergan Plc
  • Amgen Inc.
  • Biocon Ltd.
  • Biopartners GmbH
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc.
  • Dr. Reddy`s Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi
  • Intas Pharmaceuticals Ltd.
  • Mylan NV
  • Pfizer Inc.
  • Samsung Bioepis Co. Ltd.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.